Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Easywell BiomedicalsROCO:1799 +10.00%55 Net Current Asset Value is NT$0.79 as of Dec. 2025, which is 100% below its 10-year median of 17.07. GuruFocus rates ROCO:1799 with a GF Score™ of 55/100 and a GF Value™ of NT$75.62 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 609 Drug Manufacturers companies, Easywell Biomedicals ranks worse than 93.1% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Easywell Biomedicals's net current asset value per share for the quarter that ended in Dec. 2025 was NT$0.79.
The historical rank and industry rank for Easywell Biomedicals's Net Current Asset Value or its related term are showing as below:
ROCO:1799'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 9.72 Med: 17.07 Max: 247.31
Current: 45.25
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Easywell Biomedicals was 247.31. The lowest was 9.72. And the median was 17.07.
ROCO:1799's Price-to-Net-Current-Asset-Value is ranked worse than 93.1% of 609
companies
in the Drug Manufacturers industry
Industry Median: 5.67
vs ROCO:1799: 45.25
Easywell Biomedicals (ROCO:1799) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Easywell Biomedicals Net Current Asset Value Related Terms
Easywell Biomedicals Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Easywell Biomedicals's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Easywell Biomedicals Net Current Asset Value Chart
ROCO:1799 vs ZTS, UTHR: Net Current Asset Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Easywell Biomedicals's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Easywell Biomedicals Price-to-Net-Current-Asset-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Easywell Biomedicals's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Easywell Biomedicals's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of NT$0.79 mean?
Easywell Biomedicals (ROCO:1799) has a Net Current Asset Value of NT$0.79 as of Dec. 2025. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Easywell Biomedicals and its competitors. This is 95% below median its historical median of 17.07. Over the past decade, Easywell Biomedicals' Net Current Asset Value has ranged from 9.72 to 247.31. According to the industry distribution chart, Easywell Biomedicals ranks #567 out of 609 companies in the Drug Manufacturers industry, placing it in the top 93.1%.
Is Easywell Biomedicals' Net Current Asset Value too high?
Easywell Biomedicals' current Net Current Asset Value of NT$0.79 is 95% below median its 10-year median of 17.07. Over the past 10 years, this metric has ranged from a low of 9.72 to a high of 247.31. Based on the distribution chart, Easywell Biomedicals ranks #567 out of 609 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Easywell Biomedicals has a GF Score™ of 55/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Easywell Biomedicals' Net Current Asset Value compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Easywell Biomedicals ranks #567 out of 609 companies for Net Current Asset Value. This places Easywell Biomedicals in the lower half of its industry. The industry median Net Current Asset Value is 5.67. Historically, Easywell Biomedicals' own Net Current Asset Value has ranged from 9.72 to 247.31 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Drug Manufacturers company?
The median Net Current Asset Value among Drug Manufacturers companies is 5.67, based on 609 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Easywell Biomedicals and its competitors. For the Drug Manufacturers industry, the median Net Current Asset Value is 5.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Easywell Biomedicals's current Net Current Asset Value is NT$0.79, which is 95% below median its own 10-year median of 17.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Easywell Biomedicals stock overvalued right now?
Based on GuruFocus' analysis, Easywell Biomedicals (ROCO:1799) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$75.62, compared to a current price of NT$35.75 — trading 52.7% below its estimated fair value. The current Net Current Asset Value is NT$0.79, which is 95% below median its 10-year median of 17.07. Easywell Biomedicals' overall GF Score™ is 55/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Easywell Biomedicals (ROCO:1799), the current Net Current Asset Value is NT$0.79 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Easywell Biomedicals (ROCO:1799) Overvalued in 2026?
Based on GuruFocus' analysis, Easywell Biomedicals stock appears to be undervalued.
The current stock price of NT$35.75 is trading 52.7% below its estimated GF Value™ of NT$75.62.
GuruFocus considers Easywell Biomedicals to be Significantly Undervalued.
Key valuation signals for ROCO:1799:
Net Current Asset Value: NT$0.79 (95% below median its 10-year median of 17.07)
GF Value™: NT$75.62 vs. price of NT$35.75 (52.7% below fair value)
No single metric tells the full story. See the ROCO:1799 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Easywell Biomedicals Inc is engaged in drug development, manufacturing, and sales of active pharmaceutical ingredients, generic drugs, and new drugs. It focuses on complex generics, new drug delivery platforms, and regenerative medicines, with cGMP. The company's segments include the Drug Development segment and the Other segment. Geographically, the company operates in America, China, and Taiwan regions.
55GF Score
Get the complete analysis for ROCO:1799
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:1799 has been successfully added to your 
